Jpmorgan Chase & CO T Scan Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 66,756 shares of TCRX stock, worth $136,849. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66,756
Previous 31,805
109.89%
Holding current value
$136,849
Previous $158,000
27.22%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding TCRX
# of Institutions
91Shares Held
41.9MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.36MShares$11 Million6.28% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$10.3 Million0.71% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$9.15 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$7.17 Million0.02% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$6.13 Million0.34% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $38.8M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...